Semax is the peptide most likely to be described as "approved," because it is, in Russia. What that approval rests on is a body of small studies from the institutes that developed it, none of which would pass an FDA or EMA review as it stands. Here is that body of work, as far as PubMed indexes it.
What it is
Semax is a synthetic heptapeptide: the 4-to-7 fragment of adrenocorticotropic hormone (ACTH) with a Pro-Gly-Pro tail added for stability. It has no hormonal (steroid-raising) activity. It was developed at the Institute of Molecular Genetics in Moscow in the 1980s and 1990s and is used in Russia as a nasal solution after ischaemic stroke and for some cognitive and ophthalmic indications. Proposed mechanisms include increased BDNF expression and effects on brain immune and vascular gene expression, mostly demonstrated in rats.
The human evidence
| Year | Design | Result | PubMed |
|---|---|---|---|
| 1997 | 30 patients in the acute phase of hemispheric ischaemic stroke vs 80 control patients on conventional therapy; clinical scales, EEG and evoked potentials; not randomised | Better neurological scores and electrophysiological measures in the treated group, as reported by the developing group. | 11517472 |
| 2018 | 110 stroke patients in early and late rehabilitation, each split into treated and untreated subgroups; plasma BDNF, MRC scale, Barthel index | Higher BDNF and faster Barthel index improvement in treated subgroups. Open design; allocation method not described in the abstract. | 29798983 |
| 2018 | Small fMRI study of the default mode network after a single dose | Changes in network connectivity. Mechanistic, no clinical outcome. | 30225715 |
Two features of this literature matter for how much weight it bears. All of it comes from the developer's own research network and is published in Russian-language journals. None of it is double-blind and placebo-controlled in the way a regulator elsewhere would require. That does not make the findings wrong. It makes them unconfirmed.
For the use Semax is sold for in the United States, cognitive enhancement in healthy people, there is no controlled trial at all.
Regulatory status
FDA placed Semax (heptapeptide) in Category 2 on September 29, 2023. The Category 2 page (content current as of April 22, 2026) lists it as nominated but withdrawn and retains the concern: possible immunogenicity for certain routes from aggregation and impurities, and "no, or limited, safety-related information for proposed routes of administration."
The Pharmacy Compounding Advisory Committee discussed Semax on July 24, 2026, the second day of its meeting, alongside emideltide, selank and epitalon. No vote tally appeared on FDA's page when we checked. Semax is not on the 503A bulks list, is not in Category 1, and is not an ingredient of any FDA-approved drug. Russian registration has no standing under section 503A.
Safety signals
FDA's stated concern is the absence of safety data for the routes proposed in the US nomination. The Russian studies report the drug as well tolerated in the small numbers studied. Nasal administration, the studied route, and subcutaneous injection, a route it is sometimes sold for, are different exposures; nothing in the literature covers the second.
Grade: C + X
C because controlled human studies exist for post-stroke recovery, with the caveats in the table: small, open, single-source. Low confidence within the tier. X for FDA's published safety concern. Compare selank, which comes from the same laboratory tradition and has a similar evidence shape, and read how to read a peptide study on why single-source literatures need independent replication before they count for much.
Questions people ask
Is Semax an approved drug anywhere?
It is registered in Russia, where it has been used as a nasal preparation after ischaemic stroke and for some cognitive indications since the 1990s. It has never been reviewed by FDA or the European Medicines Agency, and no controlled trial has been published outside the Russian research network that developed it.
What do the stroke studies show?
The 1997 study (PubMed 11517472) compared 30 treated patients with 80 conventionally treated controls and reported better neurological recovery; it was not randomised or blinded. The 2018 study (PubMed 29798983) split 110 rehabilitation patients into treated and untreated subgroups and reported higher plasma BDNF and faster gains on the Barthel index in the treated groups. Neither design excludes bias, and neither has been independently replicated.
Is there evidence Semax improves memory or focus in healthy people?
We found no controlled trial of Semax for cognition in healthy adults. The imaging studies (PubMed 30225715) show changes in brain network activity after a dose in small groups, which is a mechanism observation and not a cognitive outcome.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (content current as of April 22, 2026) Accessed September 4, 2026.
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee Accessed September 4, 2026.
- Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997. PubMed 11517472 Accessed September 4, 2026.
- Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018. PubMed 29798983 Accessed September 4, 2026.
- Lebedeva IS et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med 2018. PubMed 30225715 Accessed September 4, 2026.
Canonical URL: https://formblendspeptides.com/peptides/semax. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.